Europe
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
No financial terms were disclosed.
The primary endpoint was a statistically significant improvement in progression-free survival for the combination versus platinum-based chemotherapy.
Pharming Group N.V. announced that its Chief Financial Officer, Robin Wright, has decided not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and that, as result of this decision, his term with the Company will end as at that date..
Nowadays the global market is pharmacovigilance is rising radically with the increasing awareness of better health facilities and growing preference to use safer medicines.
Companies from across the globe provide updates on their pipelines and business.
Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2020. We want to know how the coronavirus outbreak may be impacting your work and your workplace.
MedDay Pharmaceuticals announced its MED1003 failed to meet its primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis.
Numab Therapeutics announced the closing of its Series B financing round at a total volume of CHF 22M. New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella.
PRESS RELEASES